FDA Appeals Utah Ephedra Court Ruling, Defends Use Of Risk/Benefit Analysis
This article was originally published in The Tan Sheet
Executive Summary
FDA's use of a risk/benefit analysis to show that ephedra presented an "unreasonable risk of illness or injury" was an appropriate means of supporting the ban of the ingredient in 2004, according to the agency
You may also be interested in...
NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration
NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration
NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration